Provention Bio Up 8% on Diabetes Drug Approval
17 Noviembre 2022 - 5:57PM
Noticias Dow Jones
By Josh Beckerman
Provention Bio Inc. shares rose 8% to $8.91 after hours as the
U.S. Food and Drug Administration approved Tzield, which the agency
called the "first drug that can delay onset of Type 1
diabetes."
The injection was approved as a treatment to delay the onset of
stage 3 type 1 diabetes in adults and children 8 and older who
currently have stage 2 type 1 diabetes.
Provention said the Tzield approval "is a historic occasion for
the T1D community and a paradigm-shifting breakthrough."
Meanwhile, MacroGenics Inc. said it has earned a $60 million
milestone payment due to the approval. MacroGenics shares were up
5% at $6.89 after hours.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
November 17, 2022 18:42 ET (23:42 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Provention Bio (NASDAQ:PRVB)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Provention Bio (NASDAQ:PRVB)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024
Real-Time news about Provention Bio Inc (NASDAQ): 0 recent articles
Más de Provention Bio Inc Artículos de Noticias